New opportunities in the treatment of cutaneous lymphoid hyperplasia

Abstract

Here, we present the results of our research regarding the efficacy of photodynamic therapy (PDT) in cutaneous lymphoid hyperplasia (CLH). We observed five patients with CLH. The diagnoses were confirmed both clinically and through laboratory testing. The response to treatment was defined by the index of the modified assessment of the severity of the skin lesions scale (mSWAT). PDT (665 ± 10 nm) with topical photosensitizer application was performed once a week. The PDT course consisted of 4 ± 2 sessions. After the therapy, complete remission was achieved in four patients (80%; mSWAT 95–100%) and partial remission in one patient (20%; mSWAT 63%). Thus, PDT proved to be an effective and safe method for treating CLH.

Keywords

cutaneous pseudolymphoma / cutaneous lymphoid hyperplasia / diagnosis / photodynamic therapy

References

[1] Olisova O.Yu., Potekaev N.S. Cutaneous pseudolymphomas (etiology, clinical picture, diagnosis and treatment). Manual for physicians. Moscow: Medical Center of the Presidential Executive Office of Russian Federation; 2002. (in Russian)

[2] Олисова О.Ю., Потекаев Н.С. Псевдолимфомы кожи (этиология, клиника диагностика и лечение). Методические рекомендации. М.: Медицинский центр Управления делами Президента Российской Федерации; 2002.

[3] Nihal M., Mikkola D., Horvath N., Gilliam A., Stevens S., Spiro T., et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum. Pathol. 2003; 34(6):617-22. DOI: 10.1016/s0046-8177(03)00075-3.

[4] Tomar S., Stoll H., Grassi M., Cheney R. Treatment of cutaneous pseudolymphoma with interferon alfa-2b. J. Am. Acad. Dermatol. 2009; 60(1):172-4. DOI: 10.1016/j.jaad.2008.07.052.

[5] Stoll D. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. J. Am. Acad. Dermatol. 1983; 8(5):696-9.

[6] Stoll D. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. J. Am. Acad. Dermatol. 1983; 8(5): 696-9.

[7] El-Dars L., Statham B., Blackford S., Williams N. Lymphocytoma cutis treated with topical tacrolimus. Clin. Exp. Dermatol. 2005; 30(3):305-7.

[8] Martin S., Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin. Lymphoma Myeloma Leuk. 2011; 11(3):286-8. DOI: 10.1016/j.clml.2011.03.017.

[9] Dionyssopoulos A., Mandekou-Lefaki I., Delli F., Kourtis D., Nikolis A., Dionyssopoulou E. T- and B-cutaneous pseudolymphomas treated by surgical excision and immediate reconstruction. Dermatol. Surg. 2006; 32(12):1526-9.

[10] Taylor R., Fortney J., Pollack R., Metcalf J., Jenrette J. Radiation therapy for B-cell cutaneous lymphoid hyperplasia. Jpn. J. Radiol. 2010; 28(5):385-7. DOI: 10.1007/s11604-010-0439-8

[11] Oliveira E., Badiale G., Moraes M. Lymphocytoma cutis: Case report. An Bras. Dermatol. 2013; 88(6, Suppl. 1):128-31. DOI: 10.1590/abd1806-4841.20132320.

[12] Mikasa K., Watanabe D., Kondo C., Tamada Y., Matsumoto Y. Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma. J. Am. Acad. Dermatol. 2005; 53(5):911-2.

[13] Takeda H., Kaneko T., Harada K., Matsuzaki Y., Nakano H., Hanada K. Successful treatment of lymphadenosis benigna cutis with topical photodynamic therapy with delta-aminolevulinic acid. Dermatology. 2005; 211(3):264-6.

[14] O’Neill J., Fien S., Zeitouni N. ALA-PDT for the treatment of cutaneous pseudolymphoma: a case report. J. Drugs. Dermatol. 2010; 9(6):688-9.

RIGHTS & PERMISSIONS

Eco-Vector